| TTM
|
12/31/2025
|
12/31/2024
|
|
|---|---|---|---|
| Total Revenue
|
14,342 | 13,562 | 2,778 |
| Selling, General and Administrative Expenses
|
-18,438 | -15,064 | -6,186 |
|
Research and Development Expenses
|
-80,364 | -58,420 | -25,682 |
|
Operating Income/Expenses
|
-98,802 | -73,484 | -31,868 |
|
Total Operating Profit/Loss
|
-84,460 | -59,922 | -29,090 |
| Total Net Finance Income/Expense
|
632 | 1,951 | 1,949 |
|
Other Income/Expense, Non-Operating
|
-3,838 | -534 | -695 |
|
Non-Operating Income/Expenses, Total
|
-3,206 | 1,417 | 1,254 |
|
Pretax Income
|
-87,666 | -58,505 | -27,836 |
|
Net Income from Continuing Operations
|
-87,666 | -58,505 | -27,836 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-87,666 | -58,505 | -27,836 |
|
Net Income after Non-Controlling/Minority Interests
|
-87,666 | -58,505 | -27,836 |
|
Net Income Available to Common Stockholders
|
-87,666 | -58,505 | -27,836 |
|
Diluted Net Income Available to Common Stockholders
|
-87,666 | -58,505 | -27,836 |
| Basic EPS
|
-2.53 | -1.77 | -0.73 |
| Diluted EPS
|
-2.53 | -1.77 | -0.73 |
|
Basic Weighted Average Shares Outstanding
|
36,121.58 | 36,121.58 | 38,079 |
|
Diluted Weighted Average Shares Outstanding
|
36,121.58 | 36,121.58 | 38,079 |
| Income Statement, Supplemental
|
|||
|
EBIT
|
-88,298 | -60,456 | -29,785 |
|
EBITDA
|
-86,835 | -59,284 | -29,361 |
|
Normalized EBITDA
|
-76,585 | -54,707 | -27,621 |
|
Normalized Income
|
-77,416 | -53,928 | -26,096 |
|
Total Unusual Items
|
10,250 | 4,577 | 1,740 |
|
Total Unusual Items Excluding Goodwill
|
10,250 | 4,577 | 1,740 |
|
Tax Effect of Unusual Items
|
0 | 0 | 0 |
|
Tax Rate, Calculated
|
0.00 | 0.00 | 0.00 |
12/31/2024 - 10/16/2026
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade